TTC28: A Potential Drug Target and Biomarker (G23331)

Target Name: TTC28

NCBI ID: G23331

TTC28

TTC28: A Potential Drug Target and Biomarker

Tetratricopeptide repeat domain (TTC) is a conserved protein domain that can be found in various organisms, including humans. It is characterized by a specific repeat sequence, which is composed of four amino acids repeated in a particular order. One of the most well- studied TTCs is TTC28, which is a 28-amino acid protein that is expressed in various tissues of the body.

TTC28 has been identified as a potential drug target and biomarker due to its unique structure and the diseases it is associated with. In this article, we will discuss the molecular mechanisms underlying TTC28 and its potential as a drug target, as well as its potential as a biomarker for various diseases.

Molecular Mechanisms of TTC28

TTC28 is a member of the superfamily of TTCs, which are characterized by the presence of a specific repeat sequence in the protein sequence. The TTC repeat is composed of four amino acids: alanine, glutamic acid, aspartic acid, and glycine. This repeat is repeated in a specific order, which is alternating between alanine and glycine.

The TTC28 protein has a molecular weight of 41 kDa and a calculated pI of 6.9. It is expressed in various tissues of the body, including the brain, heart, liver, and muscle. TTC28 is also known to be involved in various signaling pathways, including the regulation of cell adhesion, cell signaling, and inflammation.

Potential Drug Target

TTC28 is a potential drug target due to its unique structure and the diseases it is associated with. One of the most promising strategies for targeting TTC28 is the use of small molecules that can modulate its activity. Several studies have shown that TTC28 is involved in various signaling pathways, including the regulation of cell adhesion and cell signaling. Therefore, small molecules that can modulate these pathways may be effective in inhibiting TTC28 activity.

In addition, TTC28 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, targeting TTC28 may be a promising strategy for the development of new treatments for these diseases.

Biomarker Potential

TTC28 has been identified as a potential biomarker for various diseases due to its unique structure and the diseases it is associated with. The TTC28 protein is expressed in various tissues of the body, including the brain, heart, liver, and muscle. Therefore, measuring the level of TTC28 in these tissues may be a promising strategy for the diagnosis and monitoring of various diseases.

One of the most promising applications of TTC28 as a biomarker is its potential to serve as a target for diagnostic tests for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells, which is thought to be caused by the buildup of certain proteins, including TTC28. Therefore, measuring the level of TTC28 in the brain may be a promising strategy for the diagnosis and monitoring of these diseases.

Another application of TTC28 as a biomarker is its potential to serve as a target for diagnostic tests for cancer. Many cancer therapies involve the inhibition of specific signaling pathways, including those that are activated by TTC28. Therefore, measuring the level of TTC28 in cancer cells may be a promising strategy for

Protein Name: Tetratricopeptide Repeat Domain 28

Functions: During mitosis, may be involved in the condensation of spindle midzone microtubules, leading to the formation of midbody

The "TTC28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets